Skip to main navigation Skip to search Skip to main content

Performance of high-dose omalizumab in chronic urticaria is predicted by initial improvement to standard dose

  • Juliette V.L. Simons*
  • , Reineke Soegiharto
  • , André C. Knulst
  • , Juul M.P.A. van den Reek
  • , Heike Röckmann
  • *Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

4 Downloads (Pure)
Original languageEnglish
Pages (from-to)3163-3165.e2
JournalJournal of Allergy and Clinical Immunology: In Practice
Volume12
Issue number11
Early online date19 Jun 2024
DOIs
Publication statusPublished - Nov 2024

Cite this